Abstract #1691

LI-RADS treatment response criteria for hepatocellular carcinoma after locoregional treatment on contrast-enhanced CT and gadoxetic acid-enhanced MRI: a retrospective validation study using pathologic diagnosis as the reference standard

Sungeun Park^1,2, Ijin Joo¹, Dong Ho Lee¹, Jae Seok Bae¹, Jeongin Yoo¹, and Joon Koo Han^1,2,3

¹Department of Radiology, Seoul National University Hospital, Seoul, Korea, Republic of, ²Department of Radiology, Seoul National University College of Medicine, Seoul, Korea, Republic of, ³Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Korea, Republic of

The liver imaging reporting and data system (LI-RADS) recently introduced a new treatment response algorithm, namely LI-RADS treatment response (LR-TR), for HCCs treated with locoregional therapy. Using pathologic tumor viability as the reference standard, our study showed that LR-TR viable category resulted in sensitivities of 67.3%/74.5% on CT and 75.5%/80.9% on Gd-EOB-MRI; and specificities of 88.6%/88.6% on CT and 80.0%/82.9% on Gd-EOB-MRI, in reviewers 1/2, respectively, which were not significantly different between CT and Gd-EOB-MRI. In addition, our modified TR criteria applying MRI ancillary features demonstrated significantly higher sensitivity (83.6%/88.2%) and comparable specificity (80.0%/77.1%) than LR-TR on CT or MRI.

This abstract and the presentation materials are available to members only; a login is required.

Join Here